Abbisko Cayman Limited

DB:8ZD Stock Report

Market Cap: €322.4m

Abbisko Cayman Valuation

Is 8ZD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8ZD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 8ZD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 8ZD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8ZD?

Key metric: As 8ZD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 8ZD. This is calculated by dividing 8ZD's market cap by their current revenue.
What is 8ZD's PS Ratio?
PS Ratio4.9x
SalesCN¥497.27m
Market CapCN¥2.43b

Price to Sales Ratio vs Peers

How does 8ZD's PS Ratio compare to its peers?

The above table shows the PS ratio for 8ZD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.9x
FYB Formycon
14x33.4%€848.4m
HPHA Heidelberg Pharma
12x16.6%€102.1m
BIO3 Biotest
1.5x3.6%€1.4b
2INV 2invest
8.1xn/a€62.7m
8ZD Abbisko Cayman
4.9x8.8%€2.6b

Price-To-Sales vs Peers: 8ZD is good value based on its Price-To-Sales Ratio (4.9x) compared to the peer average (8.9x).

Price to Sales Ratio vs Industry

How does 8ZD's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
8ZD 4.9xIndustry Avg. 8.1xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 8ZD is good value based on its Price-To-Sales Ratio (4.9x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 8ZD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8ZD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.9x
Fair PS Ratio2.6x

Price-To-Sales vs Fair Ratio: 8ZD is expensive based on its Price-To-Sales Ratio (4.9x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 8ZD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.49
€1.12
+129.6%
58.4%€2.18€0.44n/a4
Nov ’25€0.51
€1.04
+103.3%
60.0%€1.89€0.43n/a3
Oct ’25€0.42
€1.04
+144.6%
60.0%€1.89€0.43n/a3
Sep ’25€0.33
€1.04
+212.4%
60.0%€1.89€0.43n/a3
Aug ’25€0.32
€1.04
+220.1%
60.0%€1.89€0.43n/a3
Jul ’25€0.37
€1.04
+182.5%
59.7%€1.89€0.43n/a3
Jun ’25€0.34
€0.97
+181.3%
56.5%€1.88€0.42n/a4
May ’25€0.36
€0.97
+165.8%
56.5%€1.88€0.42n/a4
Apr ’25€0.31
€0.97
+214.2%
56.5%€1.88€0.42n/a4
Mar ’25€0.29
€0.93
+226.1%
54.0%€1.90€0.43n/a5
Feb ’25€0.25
€0.93
+268.3%
54.7%€1.91€0.43n/a5
Jan ’25n/a
€0.93
0%
54.7%€1.91€0.43n/a5
Dec ’24n/a
€0.86
0%
64.4%€1.92€0.38n/a5
Nov ’24n/a
€0.87
0%
70.9%€1.90€0.38€0.514
Oct ’24n/a
€0.87
0%
70.9%€1.90€0.38€0.424
Sep ’24n/a
€0.92
0%
61.5%€1.88€0.41€0.334
Aug ’24n/a
€0.78
0%
64.4%€1.75€0.38€0.325
Jul ’24n/a
€0.90
0%
63.4%€1.86€0.39€0.374
Jun ’24n/a
€0.90
0%
63.4%€1.86€0.39€0.344
May ’24n/a
€0.90
0%
64.1%€1.88€0.39€0.364
Apr ’24n/a
€0.90
0%
64.1%€1.88€0.39€0.314
Mar ’24n/a
€1.05
0%
57.6%€1.91€0.38€0.295
Feb ’24n/a
€1.07
0%
58.3%€1.98€0.38€0.255
Jan ’24n/a
€1.24
0%
38.4%€1.95€0.69n/a5
Dec ’23n/a
€1.24
0%
38.4%€1.95€0.69n/a5
Nov ’23€0.35
€1.17
+234.9%
34.4%€1.67€0.65n/a5

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.90

7D

3.6%

1Y

75.1%

Perrigo

US$3.8b

Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.

PIG

US$27.00

7D

6.8%

1Y

-3.6%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

3.6%

1Y

22.9%